Epitalon
Also known as: Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly
A four-amino-acid peptide (Ala-Glu-Asp-Gly) promoted as a telomerase-activating "longevity" compound. The anti-aging claims rest largely on a small body of older, mostly Russian studies of variable quality. Sold as a research chemical, not an approved drug.
Not approved by the FDA or in the US and EU; sold for laboratory research only. Its parent preparation (Epithalamin, a pineal peptide extract) has been used in Russia, but synthetic Epitalon is not an approved medicine in Western countries.
What it is
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — designed as a simplified analog of Epithalamin, a pineal-gland peptide extract studied in Russia. It is marketed as a “longevity” or “anti-aging” peptide on the strength of claims that it activates telomerase and lengthens telomeres. It is sold as a research chemical, not an approved medicine.
What it’s approved or studied for
Epitalon is not approved in the US or EU and is sold for laboratory research only. Its scientific interest is almost entirely in aging biology: telomere maintenance, pineal/melatonin regulation, and rodent lifespan. Most of that literature comes from a specific Russian research tradition associated with Vladimir Khavinson and colleagues.
What human evidence exists
This is the crucial caveat: the aging and telomerase claims rest largely on a small number of older studies, most from one research group, of variable and often low methodological quality, plus a handful of small Russian clinical reports that are difficult to independently verify. A 2003 cell study reported telomerase activation and telomere lengthening in human fibroblasts, and a 2025 independent cell-line study reported telomere lengthening — but this remains cell-level (Grade D) evidence. Small human reports of restored melatonin rhythms and reduced mortality in elderly cohorts are, at best, preliminary (Grade C) and would not meet modern trial standards. There is no large, independent, randomized human trial.
The major unknowns
Whether Epitalon does anything measurable for human aging, telomere length in living people, or healthspan is genuinely unknown. Telomerase activation also cuts both ways biologically — it is relevant to cancer risk — which makes the absence of modern long-term human safety data (Grade U) a serious gap, not a footnote. Human pharmacokinetics and a validated dose are also unestablished. Research-chemical purity is uncontrolled.
Most important safety considerations
There is no modern controlled human safety data, so long-term risk — including any theoretical concern tied to telomerase activation — is unstudied. Product quality is unregulated. The evidence base here is thinner and harder to verify than the marketing suggests. This page summarizes the research record; it is not medical advice or an endorsement of use.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Reported in cultured cells; foundational studies are small and mostly from one group. — A 2003 study (Khavinson et al.) reported that Epitalon induced hTERT expression, telomerase activity, and telomere elongation in human fibroblasts, letting them exceed the Hayflick limit. A 2025 independent cell-line study also reported telomere lengthening. This is cell-level (Grade D) evidence, and much of the historical record comes from a single Russian research group.
Rodent studies report longer lifespan and fewer tumors — from a narrow, older literature. — Anisimov and Khavinson's rodent work reported modest lifespan extension and reduced spontaneous tumor rates. These studies are decades old, largely from one research tradition, and have limited independent replication.
Small older human reports exist but are hard to verify and low quality. — A handful of Russian clinical reports describe restored melatonin rhythms and, in one long-running cohort, reduced mortality in elderly participants given the pineal preparation. These are small, old, methodologically limited, and difficult to independently verify — treat this as preliminary, not established.
Unknown — no modern controlled safety data.
Safety
Common adverse effects
- Not established in modern controlled studies; injection-site reactions reported anecdotally
Serious risks
- Unknown — no controlled long-term human safety data; unregulated research-chemical product quality and contamination risk
Contraindications
- No reliable human contraindication data; not approved for human use
References
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine (2003)
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology (2025)
- Epitalon — overview and regulatory status (Wikipedia)